FY2025 EPS Estimates for uniQure Cut by Cantor Fitzgerald

uniQure N.V. (NASDAQ:QURE) – Analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for uniQure in a note issued to investors on Wednesday, July 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn ($3.31) per share for the year, down from their prior estimate of ($2.76). The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. Cantor Fitzgerald also issued estimates for uniQure’s FY2026 earnings at ($3.81) EPS.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.20. The business had revenue of $5.26 million during the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.

Several other analysts have also recently weighed in on QURE. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Thursday, May 29th. Chardan Capital reduced their price target on shares of uniQure from $38.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $36.55.

uniQure Price Performance

Shares of uniQure stock opened at $13.69 on Friday. The business has a 50 day moving average of $14.83 and a 200 day moving average of $13.69. uniQure has a 52 week low of $4.45 and a 52 week high of $19.18. The company has a market cap of $751.17 million, a PE ratio of -3.49 and a beta of 0.11. The company has a quick ratio of 11.99, a current ratio of 9.98 and a debt-to-equity ratio of 1.53.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 2,112 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $295,343.55. This trade represents a 9.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the transaction, the director owned 34,190 shares of the company’s stock, valued at $494,045.50. The trade was a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock valued at $322,426 over the last three months. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in QURE. Tudor Investment Corp ET AL increased its holdings in shares of uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 1,371 shares in the last quarter. Wells Fargo & Company MN boosted its stake in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares in the last quarter. Northern Trust Corp grew its position in uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after purchasing an additional 1,923 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after purchasing an additional 3,996 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in uniQure in the second quarter worth about $117,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.